Citi lowered the firm’s price target on Zymeworks to $17 from $21 and keeps a Buy rating on the shares following the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZYME:
- Zymeworks reports Q4 EPS $4.65, consensus $4.84
- Zymeworks shareholder EcoR1 Capital buys $3.0M in company shares
- Zymeworks price target raised to $16 from $15 at Guggenheim
- Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA
- This Insider Just Spiked Investors’ Interest in Zymeworks (NASDAQ:ZYME) Stock
